Menu
1 min read · estimated
APPROVED USE
What FDA approved
Adults with mismatch repair-deficient primary advanced or recurrent endometrial cancer; use with carboplatin and paclitaxel followed by durvalumab alone.
LAMPGEN ANALYSIS
Why it matters
The indication is confined to dMMR disease; read DUO-E results in that biomarker-defined context.
What research teams should watch
Verify the MMR result before treatment and separate the FDA-approved maintenance regimen from other DUO-E study arms.
PRIMARY RECORDS